World ADC San Diego 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

ADC discovery chemistry at World ADC San Diego 2026

Oct 12–15, 2026 San Diego, CA ~1.3k attendees Website

56 organizations at World ADC San Diego 2026 present work in ADC discovery chemistry: 30 drug developers, 25 technology and service providers and 1 academic, government or non-profit body. Between them they bring 120 presentations to the program. Most represented: Merck & Co. (6 on the program), Daiichi Sankyo (5 on the program), Pfizer (4 on the program). As of Oct 8, 2026.

All 165 organizations at World ADC San Diego 2026 →

Showing 1–7 of 56 organizations

Organization	World ADC San Diego 2026 Attendance
Merck & Co. Rahway, NJ
merck.com Large pharma Global pharmaceutical company, known as MSD outside the US and Canada, with marketed cancer medicines and an ADC pipeline.	Panel Mon Oct 12 12:00pm Breaking Down Strategic Approaches to Ensure Product Quality in Late-Stage ADC Manufacturing Pre-conference: 8th CMC Day Talk Wed Oct 14 11:00am Harnessing Computational & Mechanistic Insights Into Chemoselective Reduction for Engineered Cysteine Site-Specific ADCs Discovery Chemistry Talk Wed Oct 14 12:00pm Assessing Case Study Characterization & Control of an ADC Variant to Mitigate Analytical Comparability Risk Process & Analytical Development Talk Wed Oct 14 2:00pm Mechanistic QSP Platform for ADCs in Oncology: Exploring Prospective Efficacy & Safety Predictions to Guide Study Design Translational Medicine Talk Wed Oct 14 3:00pm Evaluating Environmental Temperature as a Hidden Critical Factor in icIEF for a Late-Stage ADC Process & Analytical Development
Daiichi Sankyo Tokyo, Japan
daiichisankyo.com Large pharma Japanese pharmaceutical company behind the DXd ADC platform, including trastuzumab deruxtecan and datopotamab deruxtecan.	Panel Mon Oct 12 2:30pm Tackling Opportunities & Strategies to Identify High Risk Patients & Best Mitigate Clinical ADC Toxicities VIRTUAL PRESENTATION Pre-conference: 7th Toxicity Day Panel Tue Oct 13 8:00am Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact Plenary · with Amgen, Iksuda Therapeutics, Pfizer +1 more ADC discovery chemistryADC discovery biology Talk Tue Oct 13 2:30pm The Transition of an ADC From Late-Line to First-Line Therapy in HER2+ Breast Cancer & Earlier Line Gastric Cancer: The Trastuzumab Deruxtecan (T-DXd) Example Clinical Lessons Panel Tue Oct 13 3:30pm Assessing the Growing Importance of ADC Sequencing & Combination Approaches to Optimize Differentiated Clinical Performance Clinical Lessons Talk Wed Oct 14 2:00pm Highlighting Preclinical Development of DS-3939a, a DXd-ADC Targeting TA-MUC1 Preclinical Workshop Thu Oct 15 1:00pm Breaking Down Clinical Characterization & Differentiation Strategies to Set Up ADC Development for Success in an Increasingly Busy Oncology Landscape Post-conference workshop for Translational Medicine & Clinical Lessons · with NEOK Bio
Pfizer New York, NY
pfizer.com Large pharma Global pharmaceutical company whose oncology portfolio includes ADCs gained with Seagen, such as PADCEV.	Panel Tue Oct 13 8:00am Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact Plenary · with Amgen, Daiichi Sankyo, Iksuda Therapeutics +1 more ADC discovery chemistryADC discovery biology Talk Tue Oct 13 11:00am PF-08046033: Advancing GPNMB Targeted Auristatin-S ADC Through Payload Modification to Improve Tolerability Preclinical Talk Tue Oct 13 12:00pm Deep-Diving Into Mechanistic Insights of a Novel ADC Payload That Inhibits Protein Translation Discovery Chemistry Talk Tue Oct 13 2:00pm Setting the Scene for Novel Combination Partner Approaches for Vedotin-Based ADCs Including PADCEV – VIRTUAL PRESENTATION Clinical Lessons Panel Tue Oct 13 3:30pm What’s the New Path to the Next Generation of ADCs? Discovery Biology · with Sygnature Discovery, AstraZeneca, Iksuda Therapeutics +1 more Chair Leveraging Novel Payload MoAs & Combinations to Differentiate ADC Mechanisms & Combat Patient Resistance Discovery Chemistry Panel Wed Oct 14 2:30pm What is Showing the Most Promise & What Still Needs to be Proven in ADC Chemistry & Mechanistic Innovation? Discovery Chemistry
AstraZeneca Cambridge, UK
astrazeneca.com Large pharma Global pharmaceutical company whose ADCs include trastuzumab deruxtecan and datopotamab deruxtecan, co-developed with Daiichi Sankyo.	Chair Unlocking the Therapeutic Power of Rationale-Driven ADC Combinations Pre-conference: 10th ADCs in Combination Day Talk Mon Oct 12 10:00am Addressing ADC Regulatory Strategy for Gross Content Testing, Linker RSM Definition & Alternative Charge Variant QC for Release & Stability Pre-conference: 8th CMC Day Talk Mon Oct 12 10:00am Combining the Past, Present & Future: Learnings, Trends & Impact of the Past 10 Years of ADC Combination Therapies Pre-conference: 10th ADCs in Combination Day Talk Tue Oct 13 11:00am Evaluating CMC Projects to Ensure Sustainable, Time & Cost Sensitive Manufacturing Across the ADC Product Portfolio Manufacturing & Supply Chain Talk Tue Oct 13 11:00am PROTAC ADCs: Incorporating Historical Learnings to Navigate Novel Payload Development Beyond Blind Potency Discovery Chemistry Panel Tue Oct 13 3:30pm What’s the New Path to the Next Generation of ADCs? Discovery Biology · with Sygnature Discovery, Iksuda Therapeutics, Pfizer +1 more
Callio Therapeutics
calliotx.com Biotech Clinical-stage biotech developing dual-payload ADCs, led by a HER2-targeted program, to counter tumor resistance.	Talk Tue Oct 13 12:00pm From Complexity to Manufacturability: Considerations to Rapidly Develop & Manufacture Dual Payload ADCs Manufacturing & Supply Chain Talk Tue Oct 13 2:00pm Harnessing the Promise of Dual Payload ADCs to Combat Resistance to Traditional ADCs Discovery Chemistry Panel Tue Oct 13 3:30pm What’s the New Path to the Next Generation of ADCs? Discovery Biology · with Sygnature Discovery, AstraZeneca, Iksuda Therapeutics +1 more Panel Tue Oct 13 5:45pm Building the Next Generation of ADC Linkers & Payloads: What do Innovators Need from Development & Manufacturing Partners? Plenary · with Exelixis, Genentech, Veranova +1 more ADC discovery chemistryManufacturing & supply chain Chair Enhancing ADC Quality Characterization & Process Control to Rapidly & Confidently Produce Complex Conjugates Process & Analytical Development Talk Wed Oct 14 12:00pm Leveraging a Modular & Adaptable Linker Design to Evaluate Translation of Rationally Selected Dual Payload Combinations Preclinical
Exelixis Alameda, CA
exelixis.com Biotech Oncology company with marketed cabozantinib and a pipeline of biotherapeutics, including masked ADCs.	Chair Manufacturing Cost Efficient & Regulatory Compliant ADCs at Scale Pre-conference: 8th CMC Day Panel Mon Oct 12 10:30am Discussing Best Practices & Opportunities With Existing ADC Regulatory CMC Legislation & Data Submissions Pre-conference: 8th CMC Day Talk Mon Oct 12 10:30am Evaluating Design & Preclinical Characterization of XB404, a Masked ADC Targeting ROR1 & ROR2 Pre-conference: 3rd Pharmacology Day Talk Tue Oct 13 2:00pm Navigating Platform Process Development Approaches to Ensure mAb Readiness for Diverse Conjugation Approaches Process & Analytical Development Panel Tue Oct 13 5:45pm Building the Next Generation of ADC Linkers & Payloads: What do Innovators Need from Development & Manufacturing Partners? Plenary · with Genentech, Callio Therapeutics, Veranova +1 more ADC discovery chemistryManufacturing & supply chain Talk Wed Oct 14 12:00pm Exploring Design & Preclinical Characterization of XB773, a Novel Anti-DLL3 Targeting ADC Discovery Biology
Regeneron Tarrytown, NY
regeneron.com Large pharma Develops and markets antibody medicines, and researches new linker-payloads and bioconjugate designs beyond classic cytotoxic ADCs.	Chair Pushing the Boundary of Novel Bioconjugate Mechanisms & Design Pre-conference: 4th Novel Conjugates Day Talk Mon Oct 12 12:00pm Spotlighting Discovery of Novel Linker Payloads to Set the Path for the Next Wave of Differentiated Antibody Conjugates Pre-conference: 4th Novel Conjugates Day Panel Mon Oct 12 3:00pm Discussing the Future of ADC Chemistry & Design to Herald a New Era of Bioconjugate Innovation Pre-conference: 4th Novel Conjugates Day Panel Tue Oct 13 8:00am Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact Plenary · with Amgen, Daiichi Sankyo, Iksuda Therapeutics +1 more ADC discovery chemistryADC discovery biology Talk Wed Oct 14 12:00pm The 18-Month Journey to Clinic for ADCs: How Operational Strategy Sets The Pace for IND Manufacturing & Supply Chain Workshop Thu Oct 15 1:00pm Beyond Traditional ADCs: Breaking Down Control Strategies for Non‑Cytotoxic Bioconjugate Modalities Post-conference workshop for Process & Analytical Development · with Bristol Myers Squibb, Gilead Sciences